VAL-083 Shows Potential Against Multiple Cancers

VAL-083 is a "first-in-class" small molecule chemotherapeutic. Its unique structure provides many valuable benefits, including the targeting of DNA for its therapeutic effect and its ability to cross the blood brain barrier, critical for activity against central nervous system (CNS) tumors.

In GBM, we are part of the GBM AGILE Study which is an international registrational Phase II/III clinical study for GBM.

VAL-083 has completed two open-label, biomarker-driven, Phase II studies in MGMT-unmethylated GBM. MGMT is a DNA-repair enzyme that is associated with resistance to temozolomide, the current standard-of-care chemotherapy used in the treatment of GBM.

View Candidate

REM-001 is a Proprietary Late Stage Photodynamic Therapy (PDT) Platform

REM-001 has broad utility for the treatment of serious cutaneous oncology indications. REM-001 has been previously studied in four Phase II and/or Phase III clinical trials in patients with cutaneous metastatic breast cancer (CMBC), who had previously received chemotherapy and/or failed radiation therapy.

View Candidate

Explore Our Scientific Publications & Presentations

Dive deeper into our work by reviewing our robust catalog of scientific publications and presentations.

View Publications and Presentations